Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer
Clinical trial NCT07004712 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07004712
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-01
- Primary completion
- 2028-03-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.